Holen Sie sich die Stockscreener-App
26.64
6.39%
1.60
Handel nachbörslich:
27.00
0.36
+1.35%
Schlusskurs vom Vortag:
$25.04
Offen:
$25.31
24-Stunden-Volumen:
2.91M
Relative Volume:
0.89
Marktkapitalisierung:
$3.80B
Einnahmen:
$62.38M
Nettoeinkommen (Verlust:
$-101.59M
KGV:
-30.82
EPS:
-0.8644
Netto-Cashflow:
$-139.93M
1W Leistung:
+33.53%
1M Leistung:
+42.61%
6M Leistung:
+195.02%
1J Leistung:
+1,965%
1-Tages-Spanne:
$24.92
$26.81
1-Wochen-Bereich:
$20.09
$26.81
52-Wochen-Spanne:
$1.03
$26.81
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
26.64 | 3.80B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-23 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Is Tango Therapeutics’ New Leadership Bench Reframing Its R&D Ambitions or Its Risk Profile (TNGX)? - simplywall.st
Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? - Yahoo Finance
Tango Therapeutics (TNGX) price target increased by 32.09% to 20.06 - MSN
Tango Therapeutics (NASDAQ: TNGX) details 2026 virtual meeting, director elections and pay vote - Stock Titan
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 38,460 Shares of Stock - MarketBeat
Tango Therapeutics president sells $961k in stock - Investing.com
Tango Therapeutics (TNGX) R&D president exercises options and sells stock - Stock Titan
Tudor Investment Corp ET AL Acquires New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat - Sahm
Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push - TipRanks
Tango Therapeutics names Matthew Gall as chief financial officer By Investing.com - Investing.com South Africa
New CFO and senior leaders join Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
Tango Therapeutics names Matthew Gall as chief financial officer - Investing.com
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of ... - Bluefield Daily Telegraph
Tango brings in 3 executives to speed a pancreatic cancer drug toward approval - Stock Titan
Tango Therapeutics is the best performing healthcare stock in March - MSN
Tango Therapeutics (NASDAQ:TNGX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Tango Therapeutics Inc stock hits all-time high of 22.21 USD - Investing.com Canada
Tango Therapeutics Inc stock hits all-time high of 22.21 USD By Investing.com - Investing.com South Africa
Leerink raises Tango Therapeutics stock price target on PDAC data By Investing.com - Investing.com South Africa
Update Report: Is Tango Therapeutics Inc in a long term uptrendCEO Change & Smart Money Movement Tracker - baoquankhu1.vn
Leerink raises Tango Therapeutics stock price target on PDAC data - Investing.com
Performance Recap: Will Tango Therapeutics Inc benefit from rising consumer demand2026 Macro Moves & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Shares Gap UpTime to Buy? - MarketBeat
Momentum Shift: Will Tango Therapeutics Inc stock go up in YEARWeekly Profit Recap & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Moving Averages: Will Tango Therapeutics Inc benefit from rising consumer demandM&A Rumor & Weekly High Momentum Picks - baoquankhu1.vn
TNGX Should I Buy - Intellectia AI
Stifel and Jefferies raise targets on Tango Therapeutics (TNGX) - MSN
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets - The Globe and Mail
Symbol lookup from Yahoo Finance - Yahoo Finance Australia
Tango Therapeutics (TNGX) sees cautious analyst optimism following earnings - MSN
Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) - Insider Monkey
Tango Therapeutics (NASDAQ:TNGX) Trading Down 4.3%Here's What Happened - marketbeat.com
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
TNGX SEC FilingsTango Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Tango Therapeutics’ (TNGX) New ATM Plan Reframe Its Long‑Term Funding and Trial Risk Balance? - Sahm
Canaccord Genuity initiates coverage of Tango Therapeutics (TNGX) with buy recommendation - MSN
Tango Therapeutics stock hits all-time high at 21.84 USD By Investing.com - Investing.com Australia
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 27,000 Shares of Stock - MarketBeat
Tango a new Buy at Canaccord Genuity on 2026 catalysts - MSN
Tango Therapeutics president sells $572k in shares By Investing.com - Investing.com Canada
Tango Therapeutics (NASDAQ: TNGX) president sells 27,000 shares - Stock Titan
Tango stock is a new Buy at Canaccord Genuity (TNGX:NASDAQ) - Seeking Alpha
Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month HighHere's Why - MarketBeat
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.19%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):